Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritalin LA 6-month open-label extension in adults with childhood-onset ADHD
2011-000210-19Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Novartis. Primary endpoint: Long-term safety of Ritalin LA. Started Apr 2011; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2011-000210-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000210-19.